Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 1Classical hematology 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 58Leukemia 52Lymphoma 37Myelodysplastic Syndromes 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Lymphoma, Non-Hodgkin 22Hodgkin Disease 22Leukemia, Myeloid, Acute 18Multiple Myeloma 17Myeloproliferative Disorders 14Recurrence 12Lymphoma, Mantle-Cell 12Lymphoma, Large B-Cell, Diffuse 11Lymphoma, T-Cell, Peripheral 10Lymphoma, Follicular 10Congenital Abnormalities 10Neoplasms, Plasma Cell 9Lymphoma, B-Cell, Marginal Zone 9Leukemia, Myeloid, Chronic-Phase 9Hematologic Neoplasms 9Burkitt Lymphoma 9Anemia, Aplastic 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Waldenstrom Macroglobulinemia 7Myelodysplastic-Myeloproliferative Diseases 7Lymphoma, T-Cell 7Lymphoma, Large-Cell, Immunoblastic 7Graft vs Host Disease 7Sezary Syndrome 6Primary Myelofibrosis 6

Interventions

Cytarabine 82Etoposide 32Daunorubicin 31Idarubicin 26Filgrastim 26Mitoxantrone 22Busulfan 18Peripheral Blood Stem Cell Transplantation 17fludarabine phosphate 14Gemtuzumab 14Cyclophosphamide 14tipifarnib 11Clofarabine 10Azacitidine 10Radiotherapy 9Methotrexate 9Gene Expression Profiling 9sargramostim 8Flow Cytometry 8Granulocyte Colony-Stimulating Factor 7Decitabine 7Cyclosporine 7alvocidib 6Topotecan 6Tacrolimus 6Bortezomib 6Antilymphocyte Serum 6valspodar 5aldesleukin 5Vorinostat 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia, Myelomonocytic, Acute × Alemtuzumab × Clear all
NCT00555048 2017-05-24

Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Fred Hutchinson Cancer Center

Phase 1/2 Terminated
1 enrolled 5 charts
LymphoidMyeloidOther hematologic neoplasm

Congenital Abnormalities, Blast Crisis, Leukemia, Erythroblastic, Acute, Graft vs Host Disease, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Leukemia, Myelomonocytic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases

NCT00454480 2013-08-26

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

National Cancer Institute (NCI)

Phase 2/3 Completed
2,000 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡